Ignite Creation Date:
2024-05-06 @ 3:45 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04748601
Status:
RECRUITING
Last Update Posted:
2024-02-15
First Post:
2021-02-05
Brief Title:
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
Sponsor:
Upsher-Smith Laboratories
Organization:
Upsher-Smith Laboratories
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Parallel-Group Phase 4 Study to Evaluate the Efficacy and Safety of QudexyR XR in the Prevention of Migraine in Children 6 to 11 Years of Age
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None